2-(2-methylpropyl)-5-propan-2-yl-1H-imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2-methylpropyl)-5-propan-2-yl-1H-imidazole
• 化学式: C₁₀H₁₈N₂
• mdl: MFCD24392783
• 分子量: 166.26
• InChiKey: UMPRAKALVYBCJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS
  申请人：Dousson Cyril B.

  公开号：US20110150827A1

  公开（公告）日：2011-06-23

  Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了5,5-融合的杂芳基丙型肝炎病毒抑制剂化合物，例如，化合物的结构式I、IA或IB，包含这些化合物的药物组合物，以及其制备方法。还提供了它们用于治疗宿主体内HCV感染的方法。
• METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR
  申请人：Dousson Cyril B.

  公开号：US20120252721A1

  公开（公告）日：2012-10-04

  Provided herein are methods for treating or preventing drug-resistant hepatitis C virus infection in a subject, which comprises administering to the subject a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, for example, of Formula I, IA, or IB.

  本文提供了一种治疗或预防受体内药物耐药性丙型肝炎病毒感染的方法，包括向受体内注射一种5,5-融合杂芳烃丙型肝炎病毒抑制剂化合物，例如，公式I、IA或IB中的化合物。
• PYRIDONS AS PDK1 INHIBITORS
  申请人：Engelhardt Harald

  公开号：US20110269958A1

  公开（公告）日：2011-11-03

  The present invention encompasses compounds of general formula (1) while the groups R 4 to R 7 and the units W, L, Q a and Q H are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物，其中R4到R7和单位W、L、Qa和QH的定义如权利要求1所述，适用于治疗由过度或异常细胞增殖特征的疾病，并且它们作为具有上述特性的药物的用途。
• HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS
  申请人：Engelhardt Harald

  公开号：US20110313156A1

  公开（公告）日：2011-12-22

  The present invention encompasses compounds of general formula (1) wherein the units W, A, L, Q a and Q H are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.

  本发明涵盖了一般式（1）中的化合物，其中W，A，L，Qa和QH的定义如权利要求书中所述，适用于治疗由过度或异常细胞增殖所特征化的疾病，并且它们作为具有上述特性的药物的用途。
• Polycyclic pyridone derivative having integrase inhibitory activity
  申请人：Shionogi & Co., Ltd.

  公开号：US10011613B2

  公开（公告）日：2018-07-03

  The present invention relates to a novel compound having an antiviral effect, more specifically, a pyridone derivative having HIV integrase inhibitory activity, and a medicament containing the same, in particular, an anti-HIV agent. The compound of the present invention has integrase inhibitory activity and/or cell proliferation inhibitory activity against viruses, in particular, HIV and drug-resistant strains thereof. Thus, the compound is useful in preventing or treating various diseases, viral infections (for example, AIDS), and the like in which integrase participates.

  本发明涉及一种具有抗病毒作用的新型化合物，更具体地说，是一种具有艾滋病病毒整合酶抑制活性的吡啶酮衍生物，以及含有该化合物的药物，特别是抗艾滋病病毒药物。本发明的化合物对病毒，特别是艾滋病毒及其耐药菌株具有整合酶抑制活性和/或细胞增殖抑制活性。因此，本发明化合物可用于预防或治疗整合酶参与的各种疾病、病毒感染（如艾滋病）等。